BRPI0410876A - molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico - Google Patents

molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico

Info

Publication number
BRPI0410876A
BRPI0410876A BRPI0410876-0A BRPI0410876A BRPI0410876A BR PI0410876 A BRPI0410876 A BR PI0410876A BR PI0410876 A BRPI0410876 A BR PI0410876A BR PI0410876 A BRPI0410876 A BR PI0410876A
Authority
BR
Brazil
Prior art keywords
complement
disorder
fusion protein
inhibitory molecule
animal
Prior art date
Application number
BRPI0410876-0A
Other languages
English (en)
Inventor
Miles Andrew Nunn
Original Assignee
Evolutec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Application filed by Evolutec Ltd filed Critical Evolutec Ltd
Publication of BRPI0410876A publication Critical patent/BRPI0410876A/pt
Publication of BRPI0410876B1 publication Critical patent/BRPI0410876B1/pt
Publication of BRPI0410876B8 publication Critical patent/BRPI0410876B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)

Abstract

"MOLéCULA INIBIDORA DO COMPLEMENTO, ANTICORPO, PROTEìNA DE FUSãO, MOLéCULA DE áCIDO NUCLEICO VETOR CéLULA HOSPEDEIRA, MéTODOS PARA PREPARAR UMA MOLéCULA INIBIDORA DO COMPLEMENTO OU UM SEU EQUIVALENTE FUNCIONAL OU UMA PROTEìNA DE FUSãO, PARA IDENTIFICAR UM LIGANDO DE UMA MOLéCULA INIBIDORA DO COMPLEMENTO, OU UM SEU EQUIVALENTE FUNCIONAL, PARA TRATAR UM ANIMAL QUE ESTEJA SOFRENDO DE UMA DOENçA OU UM DISTúRBIO MEDIADOS PELO COMPLEMENTO, OU PREVENIR QUE UM ANIMAL DESENVOLVA UMA DOENçA OU UM DISTúRBIO MEDIADOS PELO COMPLEMENTO, PARA VACINAR UM ANIMAL CONTRA UMA DOENçA OU UM DISTúRBIO TRANSMITIDOS POR UM ARTRóPODE HEMATóFAGO E PARA INIBIR AS VIAS DO COMPLEMENTO CLáSSICA E ALTERNATIVA EM UMA CéLULA, TECIDO OU ORGANISMO NãO HUMANO, COMPOSIçãO, USO DE UMA MOLéCULA INIBIDORA DO COMPLEMENTO, UMA PROTEìNA DE FUSãO OU UMA MOLéCULA DE áCIDO NUCLEICO". A invenção diz respeito a inibidores do complemento, que inibem tanto a via clássica quanto a alternativa do complemento. Em particular, a invenção diz respeito a inibidores do complemento derivados das glândulas salivares de artrópodes hematófagos que inibem tanto a via clássica quanto a alternativa do complemento. A invenção também diz respeito ao uso de tais inibidores do complemento no tratamento e prevenção de doenças.
BRPI0410876A 2003-06-02 2004-06-02 composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão BRPI0410876B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0312619.0 2003-06-02
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors
GB0327386.9 2003-11-25
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Publications (3)

Publication Number Publication Date
BRPI0410876A true BRPI0410876A (pt) 2006-07-04
BRPI0410876B1 BRPI0410876B1 (pt) 2020-11-03
BRPI0410876B8 BRPI0410876B8 (pt) 2023-01-24

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410876A BRPI0410876B8 (pt) 2003-06-02 2004-06-02 composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão

Country Status (12)

Country Link
US (5) US7884188B2 (pt)
EP (1) EP1629098B1 (pt)
JP (1) JP4772667B2 (pt)
AT (1) ATE427356T1 (pt)
AU (1) AU2004242759B2 (pt)
BR (1) BRPI0410876B8 (pt)
CA (1) CA2526083C (pt)
DE (1) DE602004020334D1 (pt)
ES (1) ES2324993T3 (pt)
MX (1) MXPA05012880A (pt)
NZ (1) NZ544163A (pt)
WO (1) WO2004106369A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) * 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR101152557B1 (ko) 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (zh) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
JP5840623B2 (ja) * 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
JP2014520148A (ja) 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2017210537A1 (en) 2016-06-02 2017-12-07 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
US11730792B2 (en) 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP7629394B2 (ja) 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US20220370556A1 (en) 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1629098B1 (en) * 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks

Also Published As

Publication number Publication date
CA2526083C (en) 2017-01-17
US20180127472A1 (en) 2018-05-10
US7884188B2 (en) 2011-02-08
CA2526083A1 (en) 2004-12-09
WO2004106369A2 (en) 2004-12-09
US8993264B2 (en) 2015-03-31
US20220363726A1 (en) 2022-11-17
NZ544163A (en) 2009-06-26
ES2324993T3 (es) 2009-08-21
HK1085511A1 (en) 2006-08-25
BRPI0410876B1 (pt) 2020-11-03
MXPA05012880A (es) 2006-02-22
JP4772667B2 (ja) 2011-09-14
WO2004106369A3 (en) 2005-02-17
US9834585B2 (en) 2017-12-05
AU2004242759B2 (en) 2009-11-26
EP1629098B1 (en) 2009-04-01
AU2004242759A1 (en) 2004-12-09
BRPI0410876B8 (pt) 2023-01-24
DE602004020334D1 (de) 2009-05-14
US20160096870A1 (en) 2016-04-07
US20070141573A1 (en) 2007-06-21
JP2007536894A (ja) 2007-12-20
US20110263482A1 (en) 2011-10-27
EP1629098A2 (en) 2006-03-01
ATE427356T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
BRPI0410876A (pt) molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico
Ainsworth et al. The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms
Nimmerjahn et al. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity
NO20054292L (no) Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
BRPI0413466A (pt) anticorpos igf-1r humanos modificados
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
EA201400197A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
CY1116967T1 (el) Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη και διαγνωση καρκινου
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
NO20054958L (no) Substitulerte aminokarboksylsyrer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
BRPI0519429A2 (pt) composiÇço adequada para melhorar funÇço renal em um animal, mÉtodo para melhorar a funÇço renal em um animal, kit adequado para administrar composiÇÕes para melhorar a funÇço renal a um animal, meio para comunicar informaÇço, e, uso de uma composiÇço
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
Garnett et al. Phenotype of ribonuclease 1 deficiency in mice
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
EA200600539A1 (ru) Способ определения воздействия многокомпонентной смеси естественных продуктов на биологический профиль заболевания в пределах группы живых систем и разработка и контроль качества лекарственных препаратов на основе естественных продуктов
BR0116606A (pt) métodos e composições para detecção de compostos que modulam as respostas inflamatórias
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
Takahashi et al. Ultraviolet B irradiation induces apoptosis of keratinocytes by direct activation of Fas antigen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: EVOLUTEC LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: VARLEIGH LIMITED (GB)

B25D Requested change of name of applicant approved

Owner name: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LIMITED (VG)

B25G Requested change of headquarter approved

Owner name: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LIMITED (VG)

B25A Requested transfer of rights approved

Owner name: VOLUTION IMMUNO PHARMACEUTICALS SA (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2600, DE 03/11/2020. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS?